Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (679) 679
Paper (108) 108
Publication (105) 105
Book Review (36) 36
Conference Proceeding (27) 27
Book Chapter (3) 3
Patent (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (231) 231
gastroenterology & hepatology (193) 193
humans (178) 178
male (129) 129
gastroenterology and hepatology (117) 117
experiment (108) 108
particle physics (108) 108
physics (101) 101
high energy physics - experiment (99) 99
female (95) 95
physics - high energy physics - experiment (95) 95
inflammatory-bowel-disease (89) 89
adult (84) 84
ulcerative colitis (82) 82
high energy physics (80) 80
crohn's disease (77) 77
inflammatory bowel disease (72) 72
middle aged (72) 72
particle physics - experiment (71) 71
abridged index medicus (65) 65
animals (60) 60
fysik (54) 54
physical sciences (54) 54
natural sciences (53) 53
naturvetenskap (53) 53
nuclear experiment (51) 51
subatomic physics (43) 43
subatomär fysik (43) 43
crohns-disease (42) 42
treatment outcome (40) 40
inflammation (38) 38
infliximab (37) 37
phenomenology (37) 37
severity of illness index (37) 37
ulcerative-colitis (37) 37
care and treatment (33) 33
rats (33) 33
aged (31) 31
therapy (31) 31
inflammatory bowel diseases (30) 30
crohn disease - drug therapy (27) 27
magnetic resonance imaging (26) 26
colitis, ulcerative - drug therapy (25) 25
medical research (25) 25
rats, sprague-dawley (25) 25
astrophysics (24) 24
diagnosis (24) 24
endoscopy (24) 24
high energy astrophysical phenomena (24) 24
mice (24) 24
adolescent (23) 23
endothelium (23) 23
gastroenterology (23) 23
young adult (23) 23
efficacy (22) 22
physics of elementary particles and fields (22) 22
prospective studies (22) 22
remission (22) 22
clinical trials (21) 21
crohn disease - diagnosis (21) 21
double-blind method (21) 21
remission induction (21) 21
research (21) 21
analysis (20) 20
immunology (20) 20
patients (20) 20
crohns disease (19) 19
maintenance therapy (19) 19
medicine, experimental (19) 19
elementary particles, quantum field theory (18) 18
physics, particles & fields (18) 18
quality of life (18) 18
quantum field theories, string theory (18) 18
adhesion molecules (17) 17
anti-inflammatory agents - therapeutic use (17) 17
case-control studies (17) 17
crohn disease - pathology (17) 17
detectors (17) 17
antibodies, monoclonal - therapeutic use (16) 16
c-reactive protein (16) 16
colitis (16) 16
crohn disease - therapy (16) 16
crohn’s disease (16) 16
management (16) 16
pharmacology & pharmacy (16) 16
quality-of-life (16) 16
risk factors (16) 16
time factors (16) 16
adalimumab (15) 15
collisions (15) 15
expression (15) 15
ibd (15) 15
immunosuppressive agents - therapeutic use (15) 15
intestine (15) 15
p-selectin (15) 15
science & technology (15) 15
surgery (15) 15
tofacitinib (15) 15
azathioprine (14) 14
colitis, ulcerative - diagnosis (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
by Panés, Julian and Sandborn, William J and Schreiber, Stefan and Sands, Bruce E and Vermeire, Séverine and D'Haens, Geert and Panaccione, Remo and Higgins, Peter D R and Colombel, Jean-Frederic and Feagan, Brian G and Chan, Gary and Moscariello, Michele and Wang, Wenjin and Niezychowski, Wojciech and Marren, Amy and Healey, Paul and Maller, Eric
Gut, ISSN 0017-5749, 06/2017, Volume 66, Issue 6, pp. 1049 - 1059
ObjectiveTofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib... 
CLINICAL TRIALS | IMMUNOLOGY | Crohn'S DISEASE | LONG-TERM EXTENSION | ANTI-TNF | INFLAMMATORY-BOWEL-DISEASE | METAANALYSIS | EFFICACY | ADALIMUMAB | JANUS KINASE INHIBITOR | OPEN-LABEL | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | REMISSION | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Remission Induction | Protein Kinase Inhibitors - administration & dosage | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Crohn Disease - blood | Crohn Disease - drug therapy | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrroles - adverse effects | Adult | Female | Maintenance Chemotherapy | Treatment outcome | Care and treatment | Tofacitinib | Patient outcomes | Crohn's disease | Dosage and administration | Drug therapy | Comparative analysis | Statistical analysis | C-reactive protein | Cytokines | Clinical trials | Patients | Crohns disease | Inflammatory bowel disease | Studies | Signal transduction | Gastroenterology | TNF inhibitors | Janus kinase | Remission | Index Medicus | Abridged Index Medicus | CROHN'S DISEASE | Inflammatory Bowel Disease | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Stem cell therapy for perianal fistulas in Crohn's disease
by Panes, Julian
Gastroenterology and Hepatology, ISSN 1554-7914, 10/2016, Volume 12, Issue 10, pp. 637 - 640
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
by Sandborn, William J and Su, Chinyu and Sands, Bruce E and D’Haens, Geert R and Vermeire, Séverine and Schreiber, Stefan and Danese, Silvio and Feagan, Brian G and Reinisch, Walter and Niezychowski, Wojciech and Friedman, Gary and Lawendy, Nervin and Yu, Dahong and Woodworth, Deborah and Mukherjee, Arnab and Zhang, Haiying and Healey, Paul and Panés, Julian and OCTAVE Induction 1 OCTAVE Inductio and OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1723 - 1736
In three phase 3 trials involving patients with ulcerative colitis, tofacitinib (an oral, small-molecule Janus kinase inhibitor) was more effective as... 
RHEUMATOID-ARTHRITIS | MEDICINE, GENERAL & INTERNAL | ACTIVATION | EFFICACY | PHARMACOKINETICS | JANUS KINASE INHIBITOR | ADULTS | OPEN-LABEL | VEDOLIZUMAB | DISCOVERY | Protein Kinase Inhibitors - pharmacokinetics | Pyrroles - pharmacokinetics | Double-Blind Method | Humans | Middle Aged | Induction Chemotherapy | Male | Protein Kinase Inhibitors - adverse effects | Chi-Square Distribution | Remission Induction | Janus Kinases - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Pyrroles - adverse effects | Adult | Female | Piperidines - pharmacokinetics | Maintenance Chemotherapy | Colitis, Ulcerative - drug therapy | Pyrroles - therapeutic use | Treatment outcome | Tofacitinib | Patient outcomes | Analysis | Dosage and administration | Drug therapy | Ulcerative colitis | Inflammatory bowel disease | Studies | Colon | Gastroenterology | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
by Vermeire, Séverine, Dr|O'Byrne, Sharon, MD|Keir, Mary, PhD|Williams, Marna, PhD|Lu, Timothy T, MD|Mansfield, John C, MD|Lamb, Christopher A, MD|Feagan, Brian G, MD|Panes, Julian, MD|Salas, Azucena, PhD|Baumgart, Daniel C, MD|Schreiber, Stefan, MD|Dotan, Iris, MD|Sandborn, William J, MD|Tew, Gaik W, MSc|Luca, Diana, PhD|Tang, Meina T, PhD|Diehl, Lauri, DVM|Eastham-Anderson, Jeffrey, MS|De Hertogh, Gert, MD|Perrier, Clementine, PhD|Egen, Jackson G, PhD|Kirby, John A, PhD|van Assche, Gert, MD|Rutgeerts, Paul, MD
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 309 - 318
Summary Background Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed... 
Internal Medicine | CELLS | ADHESION | MEDICINE, GENERAL & INTERNAL | DISEASE | RECEPTOR | CD103 | INFLIXIMAB | EXPRESSION | MAINTENANCE THERAPY | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal - administration & dosage | Adult | Female | Remission Induction - methods | Colitis, Ulcerative - drug therapy | Monoclonal antibodies | Drug therapy | Health aspects | Analysis | Ulcerative colitis | Integrins | Inflammatory bowel disease | Flow cytometry | Ostomy | Biopsy | Gene expression | Drug dosages | Patients | Immune system | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Stem Cell Therapy for Perianal Fistulas in Crohn’s Disease
by Panes, Julian
Gastroenterology & Hepatology, ISSN 1554-7914, 10/2016, Volume 12, Issue 10, pp. 637 - 640
Column
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
by Schreiber, Stefan and Colombel, Jean-Frédéric and Bloomfield, Ralph and Nikolaus, Susanna and Schölmerich, Jürgen and Panés, Julian and Sandborn, William J and PRECISE 2 Study Investigators and PRECiSE 2 Study Investigators
The American Journal of Gastroenterology, ISSN 0002-9270, 07/2010, Volume 105, Issue 7, pp. 1574 - 1582
OBJECTIVES: We sought to analyze the efficacy (response and remission) and safety data from the PRECiSE 2 trial of certolizumab pegol according to duration of... 
SURGERY | TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | THERAPY | ADALIMUMAB | EFFICACY | TOP-DOWN | CDP870 | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | FACTOR-ALPHA | Certolizumab Pegol | Prognosis | Double-Blind Method | Humans | Middle Aged | Immunologic Factors - administration & dosage | Logistic Models | Male | Treatment Outcome | Immunoglobulin Fab Fragments - therapeutic use | Polyethylene Glycols - therapeutic use | Remission Induction | Polyethylene Glycols - administration & dosage | Antibodies, Monoclonal, Humanized | Immunoglobulin Fab Fragments - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Injections, Subcutaneous | Placebos | Adult | Female | Aged | Drug Therapy, Combination | Immunologic Factors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
by Sandborn, William J and Ghosh, Subrata and Panes, Julian and Vranic, Ivana and Su, Chinyu and Rousell, Samantha and Niezychowski, Wojciech and Study A3921063 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 7, pp. 616 - 624
Tofacitinib in Active Ulcerative Colitis Patients with ulcerative colitis were assigned to receive one of four doses of tofacitinib or placebo. The highest... 
RHEUMATOID-ARTHRITIS | JAK INHIBITOR | MEDICINE, GENERAL & INTERNAL | PLACEBO | INFLAMMATORY-BOWEL-DISEASE | THERAPY | EFFICACY | REJECTION | DOUBLE-BLIND | INFLIXIMAB | CP-690,550 | Double-Blind Method | Administration, Oral | Lipoproteins, HDL - blood | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Remission Induction | Dose-Response Relationship, Drug | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrroles - administration & dosage | Piperidines | Pyrimidines - adverse effects | Pyrroles - adverse effects | Adult | Female | Colitis, Ulcerative - drug therapy | Pyrroles - therapeutic use | Lipoproteins, LDL - blood | Treatment outcome | Dosage and administration | Diagnosis | Tofacitinib | Drug therapy | Ulcerative colitis | Inflammatory bowel diseases | Cytokines | Clinical trials | Patients | Bleeding | Cholesterol | Inflammatory bowel disease | Cell activation | Interleukins | Rectum | Janus kinase | Remission | Colon | Immune system | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Development of the Crohn's disease digestive damage score, the Lémann score
by Pariente, Benjamin and Cosnes, Jacques and Danese, Silvio and Sandborn, William J and Lewin, Maïté and Fletcher, Joel G and Chowers, Yehuda and D'Haens, Geert and Feagan, Brian G and Hibi, Toshifumi and Hommes, Daniel W and Irvine, E.Jan and Kamm, Michael A and Loftus, Edward V and Louis, Edouard and Michetti, Pierre and Munkholm, Pia and Oresland, Tom and Panés, Julian and Peyrin‐Biroulet, Laurent and Reinisch, Walter and Sands, Bruce E and Schoelmerich, Juergen and Schreiber, Stefan and Tilg, Herbert and Travis, Simon and van Assche, Gert and Vecchi, Maurizio and Mary, Jean‐Yves and Colombel, Jean‐Frédéric and Lémann, Marc
Inflammatory Bowel Diseases, ISSN 1078-0998, 06/2011, Volume 17, Issue 6, pp. 1415 - 1422
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An... 
illness index severity | magnetic resonance imaging | Crohn's disease | RADIOLOGIC ABNORMALITIES | HISTOLOGIC-FINDINGS | MURAL ATTENUATION | INFLAMMATORY-BOWEL-DISEASE | EARLY RHEUMATOID-ARTHRITIS | ENHANCED CT ENTEROGRAPHY | CLINICAL-TRIALS | MAGNETIC-RESONANCE | END-POINTS | ACTIVITY INDEX | GASTROENTEROLOGY & HEPATOLOGY | Severity of Illness Index | Magnetic Resonance Imaging | Colon - diagnostic imaging | Crohn Disease - diagnostic imaging | Colon - pathology | Crohn Disease - pathology | Colonoscopy | Humans | Ultrasonography | Tomography, X-Ray Computed | Disease Progression | Inflammatory bowel diseases | Computed tomography | Magnetic resonance imaging | Intestine | Data processing | Colon | Index Medicus | Organic chemistry | Chemical Sciences | Clincal Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease
by Jauregui-Amezaga, Aranzazu and Rovira, Montserrat and Marín, Pedro and Salas, Azucena and Pinó-Donnay, Susana and Feu, Faust and Elizalde, J Ignasi and Fernández-Avilés, Francesc and Martínez, Carmen and Gutiérrez, Gonzalo and Rosiñol, Laura and Carreras, Enric and Urbano, Alvaro and Lozano, Miguel and Cid, Joan and Suárez-Lledó, María and Mensa, Josep and Rimola, Jordi and Rodríguez, Sonia and Masamunt, Mari Carme and Comas, Dolors and Ruíz, Irene and Ramírez-Morros, Anna and Gallego, Marta and Ordás, Ingrid and Panés, Julian and Ricart, Elena
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1456 - 1462
ObjectiveTo evaluate the feasibility and toxicity of autologous haematopoietic stem cell transplantation (HSCT) for the treatment of refractory Crohn's disease... 
CROHN'S DISEASE | IMMUNOLOGY | INFLAMMATORY BOWEL DISEASE | BONE MARROW TRANSPLANTATION | IBD CLINICAL | Inflammatory bowel disease | Bone marrow transplantation | Crohn's disease | Immunology | Ibd clinical | SYSTEMIC-LUPUS-ERYTHEMATOSUS | AUTOIMMUNE-DISEASES | GUIDELINES | SCLEROSIS | FOLLOW-UP | EUROPEAN GROUP | GASTROENTEROLOGY & HEPATOLOGY | MARROW TRANSPLANTATION | BLOOD | Severity of Illness Index | Prospective Studies | Crohn Disease - psychology | Humans | Postoperative Complications - prevention & control | Antibiotic Prophylaxis - methods | Male | Treatment Outcome | Postoperative Complications - diagnosis | Crohn Disease - therapy | Patient Acuity | Platelet Count - methods | Crohn Disease - blood | Adolescent | Crohn Disease - diagnosis | Hematopoietic Stem Cell Transplantation - adverse effects | Monitoring, Physiologic - methods | Quality of Life | Adult | Female | Remission Induction - methods | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Care and treatment | Safety and security measures | Transplantation | Diagnosis | Patients | Health aspects | Hematopoietic stem cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
by Reinisch, Walter and Panés, Julián and Khurana, Sunil and Toth, Gabor and Hua, Fei and Comer, Gail M and Hinz, Michelle and Page, Karen and O'Toole, Margot and Moorehead, Tara McDonnell and Zhu, Hua and Sun, YanHui and Cataldi, Fabio
Gut, ISSN 0017-5749, 06/2015, Volume 64, Issue 6, pp. 894 - 900
Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was... 
CELLS | ULCERATIVE COLITIS | ULCERATIVE-COLITIS | INTERLEUKINS | RECEPTOR | ASTHMA | CYNOMOLGUS MONKEYS | GASTROENTEROLOGY & HEPATOLOGY | NEUTRALIZATION | LUNG INFLAMMATION | Leukocyte L1 Antigen Complex - analysis | Eosinophils - drug effects | Interleukin-13 - antagonists & inhibitors | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized - pharmacokinetics | Adult | Female | Leukocyte Count | Colitis, Ulcerative - drug therapy | Interleukin-13 - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Colon - pathology | Treatment Outcome | Colitis, Ulcerative - pathology | Biomarkers - blood | Colitis, Ulcerative - blood | Remission Induction | Administration, Intravenous | Feces - chemistry | Analysis of Variance | Biopsy | Adolescent | Aged | Eosinophils - cytology | Outcome and process assessment (Health Care) | Care and treatment | Research | Analysis | Interleukin-13 | Ulcerative colitis | Cytokines | Rodents | Biomarkers | TNF inhibitors | Tumor necrosis factor-TNF | Clinical medicine | Endoscopy | Molecular weight | Crohns disease | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Patient selection: which UC patient do we treat with a biologic?(ulcerative colitis)(Moving Forward in the Management of Ulcerative Colitis: A Case-Based Programme)
by Panes, Julian
Gut, ISSN 0017-5749, 09/2010, Volume 59, Issue 9, p. S2
Care and treatment | Usage | Biological products | Infliximab | Dosage and administration | Health aspects | Ulcerative colitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
by Sandborn, William J.|Panés, Julian|Zhang, Haiying|Yu, Dahong|Niezychowski, Wojciech|Su, Chinyu
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 1, pp. 96 - 102
Background & Aims Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials. We performed a post hoc analysis of... 
Gastroenterology and Hepatology | Biomarkers | Endoscopy | Tofacitinib | Mayo Score | C-REACTIVE PROTEIN | ENDOSCOPIC ACTIVITY | CROHNS-DISEASE | ACTIVE RHEUMATOID-ARTHRITIS | 2ND SCIENTIFIC WORKSHOP | TOFACITINIB CP-690,550 | INTESTINAL INFLAMMATION | INFLAMMATORY-BOWEL-DISEASE | JANUS KINASE INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Confidence Intervals | Follow-Up Studies | Area Under Curve | Humans | Leukocyte L1 Antigen Complex - metabolism | Middle Aged | Male | Dose-Response Relationship, Drug | Young Adult | Adult | Female | Colitis, Ulcerative - drug therapy | Pyrroles - therapeutic use | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Biomarkers - analysis | Treatment Outcome | Colonoscopy - methods | Feces - chemistry | Colitis, Ulcerative - diagnosis | Piperidines - therapeutic use | Pyrimidines - therapeutic use | ROC Curve | Clinical trials | Analysis | Patient outcomes | Ulcerative colitis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project
by Cleynen, Isabelle and González, Juan R and Figueroa, Carolina and Franke, Andre and McGovern, Dermot and Bortlík, Martin and Crusius, Bart J A and Vecchi, Maurizio and Artieda, Marta and Szczypiorska, Magdalena and Bethge, Johannes and Arteta, David and Ayala, Edgar and Danese, Silvio and van Hogezand, Ruud A and Panés, Julian and Peña, Salvador Amado and Lukas, Milan and Jewell, Derek P and Schreiber, Stefan and Vermeire, Severine and Sans, Miquel
Gut, ISSN 0017-5749, 11/2013, Volume 62, Issue 11, pp. 1556 - 1565
Objective Through genome-wide association scans and meta-analyses thereof, over 70 genetic loci (Crohn's disease (CD) single nucleotide polymorphisms (SNPs))... 
IBD - Genetics | VARIANTS | GENOTYPE | RISK | IBD | NOD2 | NATURAL-HISTORY | Genetic Polymorphisms | Crohn's Disease | INFLAMMATORY-BOWEL-DISEASE | FRAMESHIFT MUTATION | CARD15 | COHORT | Inflammatory Bowel Disease | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | Crohn Disease - epidemiology | Intestinal Obstruction - epidemiology | Crohn Disease - genetics | Prognosis | Colitis - genetics | Humans | Immunosuppressive Agents - therapeutic use | Male | Nod2 Signaling Adaptor Protein - genetics | Intestinal Obstruction - prevention & control | Colitis - epidemiology | Crohn Disease - complications | Young Adult | Ileitis - epidemiology | Adult | Female | Retrospective Studies | Intestinal Obstruction - etiology | Genetic Predisposition to Disease | Genome-Wide Association Study | Janus Kinase 2 - genetics | Europe - epidemiology | Models, Statistical | Disease Progression | Crohn Disease - therapy | Phenotype | Adolescent | Ileitis - genetics | Polymorphism, Single Nucleotide | Genotyping Techniques - methods | Intestinal Obstruction - genetics | Influence | Genome-wide association studies | Usage | Crohn's disease | Genetic aspects | Single nucleotide polymorphisms | Inflammatory bowel disease | Studies | Genotype & phenotype | Hospitals | Surgery | Gastroenterology | Genomes | Genetic testing | Deoxyribonucleic acid--DNA | Smoking | Crohns disease | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights